Updates

Clinigen

February 2015

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Clinigen has reported that H1 revenues have grown 17% to £72.6m (up 21% constant currency).The swing factor is the very high margin speciality pharmaceuticals side, which now has five drugs for the hospital only market. The antiviral Foscavir, which many commentators including ourselves have expected to falter, has managed to show 5% growth in sales having broadened its use. Elsewhere, cancer treatment Cardioxane started to contribute in FY14 but the final Marketing Authorisations are expected to transfer in Q3 FY15. There has also been good contributions from Ethyol (treatment for drymouth in patients treated for cancer) and Savene (oncology treatment) whilst Vibativ, an antibiotic for MRSA that has never been commercialized ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Nanoco

Emis - Sales up 30% with double digit organic growth

Clinigen (November 2016)

Clinigen (October 2016)

Clinigen (October 2015)

Clinigen (August 2015)

Clinigen - Completes £225m Idis acquisition (June 2015)

Clinigen (April 2015)

Clinigen - Acquires speciality products (September 2014)

Clinigen - Company reassures investors with trading update (August 2014)

Clinigen (March 2014)

Clinigen - Growing rapidly into valuation (February 2014)

Clinigen - On lookout for 3-5 more deals (November 2013)

Clinigen - Another upgrade to forecast (September 2013)

Clinigen - First of half a dozen deals (April 2013)

Clinigen - Acquisition anticipated in March (March 2013)

Clinigen - Trial services to grow at 17% annual clip (December 2012)

Clinigen - New issue growing like topsy (November 2012)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X